X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
humans (14) 14
female (12) 12
middle aged (11) 11
aged (10) 10
male (10) 10
cancer (9) 9
chemotherapy (8) 8
oncology (8) 8
stomach cancer (8) 8
stomach neoplasms - drug therapy (8) 8
adenocarcinoma - drug therapy (7) 7
adult (7) 7
stomach neoplasms - pathology (7) 7
adenocarcinoma (6) 6
adenocarcinoma - mortality (6) 6
cancer therapies (6) 6
analysis (5) 5
follow-up studies (5) 5
stomach neoplasms - mortality (5) 5
survival rate (5) 5
capecitabine (4) 4
docetaxel (4) 4
hematology, oncology and palliative medicine (4) 4
iii trial (4) 4
metastasis (4) 4
neoplasm staging (4) 4
treatment outcome (4) 4
young adult (4) 4
abridged index medicus (3) 3
adenocarcinoma - pathology (3) 3
adenocarcinoma - secondary (3) 3
adolescent (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
apoptosis (3) 3
carcinoma (3) 3
care and treatment (3) 3
clinical trials (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
disease-free survival (3) 3
esophageal cancer (3) 3
esophagus (3) 3
fluorouracil - administration & dosage (3) 3
fluorouracil - analogs & derivatives (3) 3
gastrectomy (3) 3
ligands (3) 3
medical colleges (3) 3
medicine, general & internal (3) 3
nivolumab (3) 3
product development (3) 3
prognosis (3) 3
proteins (3) 3
survival (3) 3
tumors (3) 3
1st-line therapy (2) 2
1st-line treatment (2) 2
activation (2) 2
aged, 80 and over (2) 2
animals (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antioxidants (2) 2
breast-cancer (2) 2
cell death (2) 2
cell lung-cancer (2) 2
chebulic acid (2) 2
cisplatin - administration & dosage (2) 2
deoxycytidine - adverse effects (2) 2
dissection (2) 2
drosophila (2) 2
enzymes (2) 2
esophagogastric junction (2) 2
esophagogastric junction - pathology (2) 2
fluorouracil - adverse effects (2) 2
gastric cancer (2) 2
gene expression (2) 2
growth factors (2) 2
health aspects (2) 2
hepatocytes (2) 2
immunity (2) 2
intention to treat analysis (2) 2
internal medicine (2) 2
kaplan-meier estimate (2) 2
kinases (2) 2
ligases (2) 2
medical research (2) 2
medicine, experimental (2) 2
neoplasm recurrence, local - drug therapy (2) 2
neoplasm recurrence, local - pathology (2) 2
organoplatinum compounds - administration & dosage (2) 2
organoplatinum compounds - adverse effects (2) 2
oxidative stress (2) 2
paclitaxel (2) 2
phosphorylation (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9813, pp. 315 - 321
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 12, pp. 1389 - 1396
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 490 - 499
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 717 - 726
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 2/2014, Volume 140, Issue 2, pp. 319 - 328
Journal Article
Brain Research, ISSN 0006-8993, 02/2019, Volume 1704, pp. 47 - 58
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors and are considered promising therapeutic targets in several neurodegenerative... 
Neuroinflammation | PPAR α/γ dual agonist | MPTP | MHY908 | Parkinson’s disease
Journal Article